Top-line data from Sage Therapeutics’ Phase III MOUNTAIN clinical trial have shown that SAGE-217 failed to meet the primary endpoint in adults with major depressive disorder (MDD).

SAGE-217 is an investigational neuroactive steroid (NAS) positive allosteric modulator (PAM) of GABAA receptor. The oral drug candidate is being developed for the treatment of depression.

The double-blind, placebo-controlled MOUNTAIN study assessed the safety and efficacy of a 20mg or 30mg once-nightly dose of SAGE-217 over two weeks in 581 MDD patients compared to placebo.

The primary endpoint was the change in the 17-item Hamilton Rating Scale for Depression (HAM-D) total score from baseline to day 15.

Secondary endpoints included the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Hamilton Anxiety Rating Scale (HAM-A) total score.

The trial did not meet its primary endpoint by failing to demonstrate a statistically significant decrease in the 17-item HAM-D total score at day 15, compared to placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Patients treated with the 30mg dose experienced a mean decrease of 12.6 in HAM-D total score versus 11.2 with placebo.

However, the 30mg dose led to statistically significant reductions in the HAM-D total score at days three, eight and 12.

SAGE-217 was generally well-tolerated with a safety profile similar to that observed in prior trials. Overall adverse events (AEs) were similar between the study groups during the treatment period and 28-day follow-up.

The most common AEs associated with SAGE-217 were headache, somnolence, dizziness, diarrhoea, sedation, nausea and fatigue.

Sage Therapeutics chief medical officer Steve Kanes said: “As a designated breakthrough therapy, we are evaluating the path forward to more fully inform a potentially expedited pathway to approval, and any amendments we might consider to the ongoing SAGE-217 pivotal programme.”

SAGE-217 is part of five additional pivotal trials. Two trials yielded positive results in MDD and postpartum depression (PPD), and three are ongoing.